ValuEngine upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a strong sell rating to a sell rating in a research note released on Friday morning.

ICPT has been the topic of a number of other research reports. Royal Bank Of Canada initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. They issued an outperform rating and a $244.00 price objective on the stock. Laidlaw cut their price objective on shares of Intercept Pharmaceuticals from $118.00 to $90.00 and set a hold rating on the stock in a research note on Friday, September 22nd. Cantor Fitzgerald upgraded shares of Intercept Pharmaceuticals from an underweight rating to a neutral rating and set a $69.00 price objective on the stock in a research note on Wednesday, November 1st. BidaskClub upgraded shares of Intercept Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 24th. Finally, Wells Fargo & Company reiterated an outperform rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $144.13.

Intercept Pharmaceuticals (NASDAQ ICPT) traded down $0.20 during midday trading on Friday, hitting $61.21. 453,900 shares of the company’s stock were exchanged, compared to its average volume of 773,988. Intercept Pharmaceuticals has a fifty-two week low of $54.98 and a fifty-two week high of $135.59. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The business’s quarterly revenue was up 697.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.59) earnings per share. equities analysts anticipate that Intercept Pharmaceuticals will post -13.35 earnings per share for the current year.

In other news, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 2,566 shares of company stock worth $151,025. Company insiders own 4.50% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in shares of Intercept Pharmaceuticals in the third quarter worth about $731,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Intercept Pharmaceuticals by 292.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,582 shares of the biopharmaceutical company’s stock worth $440,000 after buying an additional 5,648 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Intercept Pharmaceuticals by 68.6% in the third quarter. Cubist Systematic Strategies LLC now owns 6,717 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 2,734 shares in the last quarter. Cowen Inc. purchased a new position in shares of Intercept Pharmaceuticals in the third quarter worth about $1,161,000. Finally, Royce & Associates LP purchased a new position in shares of Intercept Pharmaceuticals in the third quarter worth about $1,567,000. Institutional investors and hedge funds own 73.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/intercept-pharmaceuticals-icpt-lifted-to-sell-at-valuengine/1743762.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.